| Index | — | P/E | — | EPS (ttm) | -2.78 | Insider Own | 9.01% | Shs Outstand | 41.78M | Perf Week | -5.72% |
| Market Cap | 5.41B | Forward P/E | — | EPS next Y | -2.59 | Insider Trans | -25.52% | Shs Float | 35.08M | Perf Month | 10.94% |
| Enterprise Value | 4.59B | PEG | — | EPS next Q | -0.59 | Short Float | 10.54% | Perf Quarter | 20.74% | ||
| Income | -93.00M | P/S | — | EPS this Y | — | Short Ratio | 4.76 | Perf Half Y | 23.06% | ||
| Sales | 0.00 | P/B | 6.65 | EPS next Y | — | ROA | -11.22% | Short Interest | 3.70M | Perf YTD | 280.97% |
| Book/sh | 19.48 | P/C | 6.60 | EPS next 5Y | — | ROE | -37.51% | 52W High | 146.57 -11.63% | Perf Year | — |
| Cash/sh | 19.63 | P/FCF | — | EPS past 3/5Y | — | ROIC | -12.63% | 52W Low | 32.00 304.78% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.98% 7.12% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 8.05 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 70.53 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 52.47 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 70.53 | EPS Q/Q | 56.06% | SMA20 | 1.52% | Beta | 1.02 | Target Price | 174.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | 12.52% | Rel Volume | 0.86 | Prev Close | 139.69 |
| Employees | 37 | LT Debt/Eq | 0.00 | Earnings | Nov 10 | SMA200 | 37.75% | Avg Volume | 738.69K | Price | 129.53 |
| IPO Date | Feb 04, 2026 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.43% — | Net Debt/EBITDA | — | Volume | 635,265 | Change | -7.27% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-22-26 | Reiterated | UBS | $170 → $204 | |
| Jul-15-26 | Initiated | B. Riley | Buy | $170 |
| Jul-07-26 | Reiterated | Jefferies | Buy | $75 → $182 |
| Jun-02-26 | Initiated | Needham | Buy | $136 |
| Mar-02-26 | Reiterated | Jefferies | $75 |
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 27 | 10 | 3 | 2 | |
| Research and Development | 76 | 62 | 23 | 15 | |
| Other Operating Expense | 0 | 0 | 1 | 0 | |
| Operating Income | -103 | -72 | -27 | -17 | |
| Interest Expense | 1 | 0 | 1 | 0 | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 11 | 2 | 1 | 1 | |
| Net Income Before Taxes | -93 | -70 | -26 | -16 | |
| Income Taxes | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -93 | -70 | -26 | -16 | |
| Net Income From Continuing Operations | -93 | -70 | -26 | -16 | |
| Net Income | -93 | -70 | -26 | -16 | |
| EPS (Recurring) | -2.78 | -2.38 | -0.14 | -0.08 | |
| EPS (Basic, Before Extraordinaries) | -2.78 | -2.38 | -0.14 | -0.08 | |
| EPS (Diluted) | -2.78 | -2.38 | -0.14 | -0.08 | |
| EBITDA | -97 | -70 | -26 | -16 | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | — | — | — | |
| Operating Margin | — | — | — | — | |
| Net Margin | — | — | — | — | |
| Shares Outstanding | 40 | 35 | 201 | 201 | |
| Market Capitalization | 5,181 | — | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | Director | Aug 20 '26 | Option Exercise | 0.00 | 300,000 | 0 | 3,106,937 | Aug 21 |
| MONTANOVA CAPITAL, LLC | Director | Aug 19 '26 | Sale | 107.25 | 750,000 | 80,437,500 | 461,033 | Aug 21 |
| Waldman Reid Alexander | Chief Executive Officer | Aug 17 '26 | Option Exercise | 12.19 | 3,452 | 42,080 | 238,324 | Aug 18 |
| Waldman Reid Alexander | Chief Executive Officer | Aug 17 '26 | Sale | 107.86 | 67,500 | 7,280,713 | 170,824 | Aug 18 |
| Durso Timothy August | Chief Technical Officer | Aug 17 '26 | Sale | 107.82 | 43,500 | 4,690,004 | 78,142 | Aug 18 |
| Durso Timothy August | Chief Technical Officer | Aug 17 '26 | Option Exercise | 12.19 | 3,452 | 42,080 | 121,642 | Aug 18 |
| CHILDS JOHN W | Director | Aug 12 '26 | Sale | 107.12 | 100,000 | 10,711,700 | 194,117 | Aug 14 |